Nordgren A (2001) Responsible genetics. The moral responsibility of geneticists for the conse-
quences of human genetic research. Kluwer, Dordrecht
Pavelic ́K, Martinovic ́T, Kraljevic ́-Pavelic ́S (2015) Do we understand the personalized medicine
paradigm? EMBO Rep 16(2):133–136
Personalized Medicine Coalition (2014) The case for personalized medicine, 4th edn.http://www.
personalizedmedicinecoalition.org/communications/theCaseforPersonalizedMedicine-11-13.
pdf. Accessed 12 Feb 2015
Qattan M, Demonacos C, Krstic-Demonacos M (2012) Roadmap to personalized medicine. Croat
Med J 53:294–297
Radder JE, Shapiro SD, Berndt A (2014) Personalized medicine for chronic, complex diseases:
chronic obstructive pulmonary disease as an example. Pers Med 11(7):669–679
Radolovic ́A (2006) Pravo osobnosti u novom Zakonu o obveznim odnosima. Zb Prav fak Sveucˇ
Rij 27(1):129–170
Raspe H (2012) Personalisierte Medizin – Ende der Solidarita ̈t. In: Personalisierte Medizin – der
Patient als Nutznießer oder Opfer, Tagungsdokumentation, Jahrestagung des Deutschen
Ethikrates, pp 59–70
Regulation EU No 536/2014 of the European Parliament and of the Council on clinical trials on
medicinal products for human use, and repealing Directive 2001/20/EC, OJ L 158 of
27.05.2014
Rugnetta M, Kramer W (2009) Paving the way for personalized medicine: facilitating inter-agency
coordination for the integration science progress.www.scienceprogress.org/2009/09/personal
ized-medicine. Accessed 8 Nov 2014
Taupitz J (2011) Individualisierte Medizin: die internationalrechtliche Perspektive. In:
Schumpelick V, Vogel B (eds) Medizin nach Maß. Individualisierte Medizin – Wunsch und
Wirklichkeit. Herder, Freiburg, pp 219–238
The American Recovery and Reinvestment Act of 2009, Pub.L. 111–5; 123 Stat. 115
The Americans with Disabilities Act, Pub.L. 101–336, 104 Stat. 327
The Electronic Communication Privacy Act of 1986, 18 U.S.C.§2510-2521, 2701–2710
The Genetic Information Nondiscrimination Act of 2008, Pub.L. 110–233, 122 Stat. 881
The Health Insurance Portability and Accountability Act, Pub.L. 104–191; 110 Stat. 1936
The Privacy Act of 1974, 5 U.S.C.§552a
The Royal Society and the Royal Academy of Engineering (2004) Nanoscience and nanotechnol-
ogies: opportunities and uncertainties.https://royalsociety.org/~/media/Royal_Society_Con
tent/policy/publications/2004/9693.pdf. Accessed 10 Nov 2014
U.S. Food and Drug Administration (2007a) Draft Guidance for Industry, Clinical Laboratories,
and FDA Staff – In Vitro Diagnostic Multivariate Index Assays,http://www.fda.gov/
RegulatoryInformation/Guidances/ucm079148.htm. Accessed 10 Dec 2014
U.S. Food and Drug Administration (2007b) Guidance for Industry and FDA Staff – Commercially
Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions.http://www.fda.
gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm078423.htm.
Accessed 10 Dec 2014
United Nations (2000) Millennium development goals.www.un.org/millenniumgoals/. Accessed
13 May 2014
Vogenberg FR, Isaacson Barash C, Pursel M (2010a) Personalized medicine. Part 2: Ethical, legal
and regulatory issues. P T 35(11):624–642
Vogenberg FR, Isaacson Barash C, Pursel M (2010b) Personalized medicine. Part 3: Challenges
facing health care plans in implementing coverage policies for pharmacogenomics and genetic
testing. P T 35(12):670–675
Wiese G (2005) Zu einer gesetzlichen Regelung genetischer Untersuchungen im Arbeitsleben.
Betriebs-Berater 2073–2083
Wiese G (2009) Gendiagnostikgesetz und Arbeitsleben. Betriebs-Berater 41:2198–2207
Challenges of Personalized Medicine: Socio-Legal Disputes and Possible Solutions 51